Fig. 7.
DFSs at 2 years of 165 patients who received cyclosporine/methotrexate, 50.4% (◊) and 164 patients who received tacrolimus/methotrexate 40.5% (□); absolute difference = 9.9%, 95% CI = −20.7 to 0.8 (P = .01, Wilcoxon).
DFSs at 2 years of 165 patients who received cyclosporine/methotrexate, 50.4% (◊) and 164 patients who received tacrolimus/methotrexate 40.5% (□); absolute difference = 9.9%, 95% CI = −20.7 to 0.8 (P = .01, Wilcoxon).
